Uploaded August 2021 | Updated November 2026, 3 hours ago
"The endocannabinoid system (ECS) is a widespread neuromodulatory system that plays important roles in central nervous system (CNS) development, synaptic plasticity, and the response to endogenous and environmental insults. The ECS is comprised of cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes responsible for the synthesis and degradation of the endocannabinoids. The most abundant cannabinoid receptor is the CB1 cannabinoid receptors, however CB2 cannabinoid receptors, transient receptor potential (TRP) channels, and peroxisome proliferator activated receptors (PPAR’s) are also engaged by some cannabinoids. Exogenous cannabinoids, such as tetrahydrocannabinol, produce their biological effects through their interactions with cannabinoid receptors. 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide) are the best-studied endogenous cannabinoids. Despite similarities in chemical structure, 2-AG and anandamide are synthesized and degraded by distinct enzymatic pathways, which impart fundamentally different physiological and pathophysiological roles to these two endocannabinoids. Because of the pervasive social use of cannabis and the involvement of endocannabinoids in a multitude of biological processes, much has been learned about the physiological and pathophysiological roles of the ECS."
ncbi.nlm.nih.gov/pmc/articles/PMC4789136
"The endocannabinoid system (ECS) has emerged as an important neuromodulatory system over the last twenty-five years. Relevant to the topic of this special issue of Biological Psychiatry, perturbations of the ECS are involved in several psychiatric disorders, including schizophrenia. The ECS is comprised of endogenous cannabinoids (endocannabinoids), cannabinoid receptors, and the enzymes responsible for the synthesis and degradation of endocannabinoids (Fig. 1). Each of these components will be introduced in this chapter, with an emphasis on their potential involvement in psychosis.
Endogenous cannabinoids are endogenous lipids that engage cannabinoid receptors (see below), affecting behavior in a fashion that at least partially recapitulates the effects produced by the psychoactive components of cannabis, most notably Δ-9-THC ((–)-trans-Δ9-tetrahydrocannabinol; THC). The first discovered and best-characterized endocannabinoids are anandamide (arachidonoyl ethanolamide) and 2-arachidonoyl glycerol (2-AG). An important feature of these endocannabinoids is that their precursors are present in lipid membranes. Upon demand (typically by activation of certain G protein-coupled receptors or by depolarization), endocannabinoids are liberated in one or two rapid enzymatic steps and released into the extracellular space. This contrasts with classical neurotransmitters that are synthesized ahead of time and stored in synaptic vesicles. The intrinsic efficacy of the endogenous cannabinoids varies—2-AG is a high efficacy agonist for both CB1 and CB2 receptors, however anandamide is a low efficacy agonist at CB1 receptors and a very low efficacy agonist at CB2 receptors (1, 2). Thus, in systems with low receptor expression or when receptors couple weakly to signaling pathways anandamide can antagonize the effects of more efficacious agonists (3). Additional endogenous substances (e.g., virodhamine and 2-arachidonoyl glycerol ether (4)) may expand the repertoire of endocannabinoids, however the biology of these compounds are not as well developed as the biology of anandamide and 2-AG, so they will not be considered further in this review. This chapter will introduce the components of the endocannabinoid system and discuss their role in modulating synaptic transmission. Chapters 6 and 8 will consider the extensive functions of cannabinoids in neurodevelopment and how perturbation of these functions may increase an individual’s risk to develop a psychiatric disorder."
In Solidarity,
Chela & Dave
cannabishelpsdementia.com
Podcast https://anchor.fm/cannabishelpsdementia
Twitter twitter.com/CannabisHelps
FB facebook.com/CHDPodcast
IG instagram.com/cannabishelpsdementia
Review us on iTunes podcasts.apple.com/us/podcast/cannabis-helps-dementia/id1506761684
#ECS #Cannabis #endocannabinoid
"The endocannabinoid system (ECS) is a widespread neuromodulatory system that plays important roles in central nervous system (CNS) development, synaptic plasticity, and the response to endogenous and environmental insults. The ECS is comprised of cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes responsible for the synthesis and degradation of the endocannabinoids. The most abundant cannabinoid receptor is the CB1 cannabinoid receptors, however CB2 cannabinoid receptors, transient receptor potential (TRP) channels, and peroxisome proliferator activated receptors (PPAR’s) are also engaged by some cannabinoids. Exogenous cannabinoids, such as tetrahydrocannabinol, produce their biological effects through their interactions with cannabinoid receptors. 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide) are the best-studied endogenous cannabinoids. Despite similarities in chemical structure, 2-AG and anandamide are synthesized and degraded by distinct enzymatic pathways, which impart fundamentally different physiological and pathophysiological roles to these two endocannabinoids. Because of the pervasive social use of cannabis and the involvement of endocannabinoids in a multitude of biological processes, much has been learned about the physiological and pathophysiological roles of the ECS."
ncbi.nlm.nih.gov/pmc/articles/PMC4789136
"The endocannabinoid system (ECS) has emerged as an important neuromodulatory system over the last twenty-five years. Relevant to the topic of this special issue of Biological Psychiatry, perturbations of the ECS are involved in several psychiatric disorders, including schizophrenia. The ECS is comprised of endogenous cannabinoids (endocannabinoids), cannabinoid receptors, and the enzymes responsible for the synthesis and degradation of endocannabinoids (Fig. 1). Each of these components will be introduced in this chapter, with an emphasis on their potential involvement in psychosis.
Endogenous cannabinoids are endogenous lipids that engage cannabinoid receptors (see below), affecting behavior in a fashion that at least partially recapitulates the effects produced by the psychoactive components of cannabis, most notably Δ-9-THC ((–)-trans-Δ9-tetrahydrocannabinol; THC). The first discovered and best-characterized endocannabinoids are anandamide (arachidonoyl ethanolamide) and 2-arachidonoyl glycerol (2-AG). An important feature of these endocannabinoids is that their precursors are present in lipid membranes. Upon demand (typically by activation of certain G protein-coupled receptors or by depolarization), endocannabinoids are liberated in one or two rapid enzymatic steps and released into the extracellular space. This contrasts with classical neurotransmitters that are synthesized ahead of time and stored in synaptic vesicles. The intrinsic efficacy of the endogenous cannabinoids varies—2-AG is a high efficacy agonist for both CB1 and CB2 receptors, however anandamide is a low efficacy agonist at CB1 receptors and a very low efficacy agonist at CB2 receptors (1, 2). Thus, in systems with low receptor expression or when receptors couple weakly to signaling pathways anandamide can antagonize the effects of more efficacious agonists (3). Additional endogenous substances (e.g., virodhamine and 2-arachidonoyl glycerol ether (4)) may expand the repertoire of endocannabinoids, however the biology of these compounds are not as well developed as the biology of anandamide and 2-AG, so they will not be considered further in this review. This chapter will introduce the components of the endocannabinoid system and discuss their role in modulating synaptic transmission. Chapters 6 and 8 will consider the extensive functions of cannabinoids in neurodevelopment and how perturbation of these functions may increase an individual’s risk to develop a psychiatric disorder."
In Solidarity,
Chela & Dave
cannabishelpsdementia.com
Podcast https://anchor.fm/cannabishelpsdementia
Twitter twitter.com/CannabisHelps
FB facebook.com/CHDPodcast
IG instagram.com/cannabishelpsdementia
Review us on iTunes podcasts.apple.com/us/podcast/cannabis-helps-dementia/id1506761684
#ECS #Cannabis #endocannabinoid










